

Blujepa (gepotidacin)
Effective 02/01/2026

| | | | | |
|------------------------------|---|--|--|--|
| Plan | <input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange | | Program Type | <input checked="" type="checkbox"/> Prior Authorization |
| Benefit | <input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit | | | <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy |
| Specialty Limitations | N/A | | | |
| Contact Information | Medical Benefit Pharmacy Benefit | | Phone: 833-895-2611 Phone: 800-711-4555 | Fax: 888-656-6671 Fax: 844-403-1029 |
| Exceptions | N/A | | | |

Overview

Blujepa (gepotidacin) is a triazacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms:

- *Escherichia coli*
- *Klebsiella pneumoniae*
- *Citrobacter freundii* complex
- *Staphylococcus saprophyticus*
- *Enterococcus faecalis*

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all the following criteria are met:

1. Diagnosis of uncomplicated urinary tract infection (uUTI)
2. Member has had a trial and inadequate response, contraindication, or resistance to one alternative oral antibiotic treatment option (e.g., ciprofloxacin, trimethoprim/sulfamethoxazole, nitrofurantoin)
3. Member's infection is caused by at least one of the following microorganisms:
 - a. *Escherichia coli*
 - b. *Klebsiella pneumoniae*
 - c. *Citrobacter freundii* complex
 - d. *Staphylococcus saprophyticus*
 - e. *Enterococcus faecalis*

Limitations

1. Approvals will be granted for 14 days
2. The following quantity limit applies:

| Drug Name and Dosage Form | Quantity Limitation |
|---------------------------|---------------------|
| Blujepa 750 mg tablet | 20 tablets per fill |

References

1. Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. *Antimicrob Agents Chemother*. 2016;60(3):1918-23. doi: 10.1128/AAC.02820-15
2. Blujepa (gepotidacin) [prescribing information]. GlaxoSmithKline; March 2025.
3. Gibson EG, Bex B, Chan PF, Osheroff N. Mechanistic and structural basis for the actions of the antibacterial gepotidacin against *Staphylococcus aureus* gyrase. *ACS Infect Dis*. 2019 Apr 12;5(4):570-581. doi: 10.1021/acsinfecdis.8b00315
4. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Disease. *Clin Infect Dis*. 2011;52:e103-e120. doi: 10.1093/cid/ciq257
5. Infectious Diseases Society of America (IDSA). IDSA practice guideline highlights and status. IDSA. 2025. Accessed April 21, 2025. <https://www.idsociety.org/practice-guideline/guideline-highlights/>
6. Kaye KS, Gupta V, Mulgirigama A, et al. Antimicrobial resistance trends in urine *Escherichia coli* isolates from adult and adolescent females in the United States from 2011 to 2019: Rising ESBL Strains and Impact on Patient Management, *Clin Infect Dis*. 2021;73(11):1992-1999.
7. Medina M, Castillo-Pino E. An introduction to the epidemiology and burden of urinary tract infections. *Ther Adv Urol*. 2019;11:3-7. doi:10.1177/1756287219832172

Review History

11/12/2025 – Reviewed at November P&T. Effective 02/01/2026.

